GeneFluidics, based in Duarte, CA, is a pioneering company that was established in 2000 with the aim of developing a cutting-edge testing system to enhance global health. By combining innovative bionano and microfluidic technologies, their revolutionary platform allows for complex tests that are typically conducted in laboratories by skilled technicians to be performed by anyone, anywhere. With a simple process that involves introducing a raw sample into a disposable cartridge and waiting for the results, GeneFluidics' platform offers fast, accurate, and user-friendly testing solutions.
With a focus on nanotechnology-enabled analyte detection and microfluidic-based automated sample preparation, GeneFluidics' platform was initially conceived as part of a biodefense program. Over the years, the company has achieved significant milestones, including being selected as a finalist for the Antimicrobial Resistance Diagnostic (AMR) Challenge Step 2 and obtaining CE-IVD marking for their UtiMax uropathogen identification and antimicrobial susceptibility testing (AST). Additionally, GeneFluidics has received funding from the National Institute of Allergy and Infectious Diseases (NIAID) for the development and clinical validation of diagnostics, further solidifying their position as a leader in the field.
Generated from the website